Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6307–6313 | Cite as

Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma

  • Wei Dai
  • Quangen Gao
  • Jianping Qiu
  • Jianmao Yuan
  • Guoliang Wu
  • Genhai Shen
Original Article

Abstract

Quercetin (Q), a flavonoid compound, which is obtained in variety of fruits, seeds, and vegetables, has been reported to possess many pharmacological properties including cancer-preventive and anticancer effects. However, studies on the anticancer effects and underlying mechanisms of Q in human hepatocellular carcinoma (HCC) are still limited. The present study is conducted to investigate the anticancer efficacy and adjuvant chemotherapy action of Q in HCC. HCC cell lines HepG2 and SMCC-7721 were treated with different concentrations of Q. The antiproliferative effects of Q were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the apoptosis and cell cycle dynamics were assessed by flow cytometry; the expression of apoptosis-associated proteins were evaluated by Western blot and immunohistochemistry staining; the tumor growth in vivo was evaluated in a xenograft mouse model. Our results showed that Q effectively inhibited human HCC cell proliferation and induced apoptosis by upregulating the expression of Bad and Bax and downregulating the expression of Bcl-2 and Survivin in vitro. Furthermore, Q obviously inhibited the tumor growth and enhanced the 5-fluorouracil (5-FU) therapeutic efficacy in vitro and in vivo. Taken together, our findings highlight that Q effectively inhibited the growth of tumor and enhanced the sensitivity to thermotherapy, indicating Q is a potential treatment option for HCC.

Keywords

Quercetin Hepatocellular carcinoma Cell proliferation Apoptosis 

Notes

Compliance with ethical standards

Conflicts of interest

None

Ethical approval

Patient material was obtained with the approval of the ethical committee of the Soochow University and patient agreement. All mouse experiments were approved by the Committee of Care and Use of Laboratory Animals of Yonsei University College of Medicine and performed in accordance with institutional guidelines and policies. The mouse experiments were approved by the Committee of Care and Use of Laboratory Animals of Soochow University of Medicine and performed in accordance with institutional guidelines and policies.

Supplementary material

13277_2015_4501_Fig5_ESM.gif (39 kb)
Fig. S1

Quercetin increases the expression of Bad and Bax and decrease Bcl-2 and Survivin expression in hepatic cancer cells. HepG2 and SMCC-7721 cells were treated as described above, and the expression of Bad, Bax, Bcl-2 and Survivin were analyzed by western blot. β-Actin served as a control. The relative gray-values (CO = 100 % or Q 0.15 mM group = 100 %) of corresponding bands were calculated and showed in diagrams. The data are presented as means ± SD (**P < 0.01, *P < 0.05). (GIF 39 kb)

13277_2015_4501_MOESM1_ESM.tif (905 kb)
High resolution (TIF 905 kb)

References

  1. 1.
    Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I. Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J. 2011;8:496.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    European Association For The Study Of The, L., R. European Organisation For, and C. Treatment Of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar
  3. 3.
    European Association for Study of, L., R. European Organisation for, and C. Treatment of. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641.CrossRefGoogle Scholar
  4. 4.
    Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(05):330–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang C, Kolb A, Buchler P, Cato AC, Mattern J, Rittgen W, et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer. 2006;6:61.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lee SH, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, et al. Q enhances chemosensitivity to gemcitabine in lung cancer cells by inhibiting heat shock protein 70 expression. Clin Lung Cancer. 2015;16(6):e235–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low concentration of Q antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One. 2014;9(7):e100314.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231–7.PubMedGoogle Scholar
  9. 9.
    Lee RH, Cho JH, Jeon YJ, Bang W, Cho JJ, et al. Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1). Drug Dev Res. 2015.Google Scholar
  10. 10.
    Sudan S, Rupasinghe HV. Antiproliferative activity of long chain acylated esters of Q-3-O-glucoside in hepatocellular carcinoma HepG2 cells. Exp Biol Med (Maywood). 2015;240(11):1452–64.CrossRefGoogle Scholar
  11. 11.
    Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Richardson A, Kaye SB. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008;1(3):244–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Smith DM, Gao G, Zhang X, Wang G, Dou QP. Regulation of tumor cell apoptotic sensitivity during the cell cycle (review). Int J Mol Med. 2000;6(5):503–7.PubMedGoogle Scholar
  14. 14.
    Bajwa N, Liao C, Nikolovska-Coleska Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat. 2012;22(1):37–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010;20(12):1723–37.CrossRefPubMedGoogle Scholar
  16. 16.
    Golbano JM, Loppez-Aparicio P, Recio MN, Perez-Albarsanz MA. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008;32(4):919–24.PubMedGoogle Scholar
  17. 17.
    Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17(14):3878–85.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res. 2002;8(2):607–14.PubMedGoogle Scholar
  19. 19.
    Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 2007;7:4.CrossRefPubMedGoogle Scholar
  20. 20.
    Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P, et al. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. Oncotarget. 2015;6(13):11547–60.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Wei Dai
    • 1
  • Quangen Gao
    • 1
  • Jianping Qiu
    • 1
  • Jianmao Yuan
    • 1
  • Guoliang Wu
    • 1
  • Genhai Shen
    • 1
  1. 1.Department of General SurgeryWujiang No.1 People’s HospitalSuzhouChina

Personalised recommendations